PT - JOURNAL ARTICLE AU - Brüningk, Sarah C. AU - Klatt, Juliane AU - Stange, Madlen AU - Mari, Alfredo AU - Brunner, Myrta AU - Roloff, Tim-Christoph AU - Seth-Smith, Helena M.B. AU - Schweitzer, Michael AU - Leuzinger, Karoline AU - Søgaard, Kirstine K. AU - Torres, Diana Albertos AU - Gensch, Alexander AU - Schlotterbeck, Ann-Kathrin AU - Nickel, Christian H. AU - Ritz, Nicole AU - Heininger, Ulrich AU - Bielicki, Julia AU - Rentsch, Katharina AU - Fuchs, Simon AU - Bingisser, Roland AU - Siegemund, Martin AU - Pargger, Hans AU - Ciardo, Diana AU - Dubuis, Olivier AU - Buser, Andreas AU - Tschudin-Sutter, Sarah AU - Battegay, Manuel AU - Schneider-Sliwa, Rita AU - Borgwardt, Karsten M. AU - Hirsch, Hans H. AU - Egli, Adrian TI - Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area AID - 10.1101/2020.12.15.20248130 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.15.20248130 4099 - http://medrxiv.org/content/early/2021/06/21/2020.12.15.20248130.short 4100 - http://medrxiv.org/content/early/2021/06/21/2020.12.15.20248130.full AB - Background Transmission chains within small urban areas (accommodating∼30% of the European population) greatly contribute to case burden and economic impact during the ongoing COVID-19 pandemic, and should be a focus for preventive measures to achieve containment. Here, at very high spatio-temporal resolution, we analysed determinants of SARS-CoV-2 transmission in a European urban area, Basel-City (Switzerland). Methodology. We combined detailed epidemiological, intra-city mobility, and socioeconomic data-sets with whole-genome-sequencing during the first SARS-CoV-2 wave. For this, we succeeded in sequencing 44% of all reported cases from Basel-City and performed phylogenetic clustering and compartmental modelling based on the dominating viral variant (B.1-C15324T; 60% of cases) to identify drivers and patterns of transmission. Based on these results we simulated vaccination scenarios and corresponding healthcare-system burden (intensive-care-unit occupancy). Principal Findings. Transmissions were driven by socioeconomically weaker and highly mobile population groups with mostly cryptic transmissions, whereas amongst more senior population transmission was clustered. Simulated vaccination scenarios assuming 60-90% transmission reduction, and 70-90% reduction of severe cases showed that prioritizing mobile, socioeconomically weaker populations for vaccination would effectively reduce case numbers. However, long-term intensive-care-unit occupation would also be effectively reduced if senior population groups were prioritized, provided there were no changes in testing and prevention strategies. Conclusions. Reducing SARS-CoV-2 transmission through vaccination strongly depends on the efficacy of the deployed vaccine. A combined strategy of protecting risk groups by extensive testing coupled with vaccination of the drivers of transmission (i.e. highly mobile groups) would be most effective at reducing the spread of SARS-CoV-2 within an urban area.Author summary We examined SARS-CoV-2 transmission patterns within a European city (Basel, Switzerland) to infer drivers of the transmission during the first wave in spring 2020. The combination of diverse data (serological, genomic, transportation, socioeconomic) allowed us to combine phylogenetic analysis with mathematical modelling on related cases that were mapped to a residential address. As a result we could evaluate population groups driving SARS-CoV-2 transmission and quantify their effect on the transmission dynamics. We found traceable transmission chains in wealthier or more senior population groups and cryptic transmissions in the mobile, young or socioeconomic weaker population groups - these were identified as transmission drivers of the first wave. Based on this insight, we simulated vaccination scenarios for various vaccine efficacies to reflect different approaches undertaken to handle the epidemic. We conclude that vaccination of the mobile inherently younger population group would be most effective to handle following waves.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04351503Funding StatementNo dedicated funding was used for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the local ethical committee Ethik Kommission Nordwest und Zentralschweiz (EKNZ No. 2020-00769, to be found at https://ongoingprojects.swissethics.ch) and the project was registered at clinicaltrial.gov under NCT04351503.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SEIR-model code used for this submission will be available on https://github.com/BorgwardtLab/BaselEpi.git. Code that was used for phylogenetic inference and calculation of significance of clusters in specified groups is available at https://github.com/appliedmicrobiologyresearch. SARS-CoV-2 whole genomes from Basel-City are available at gisaid.com and at European Nucleotide Archive (ENA) under accession number PRJEB39887. https://github.com/appliedmicrobiologyresearch https://github.com/BorgwardtLab/BaselEpi